| abstract |
Novel spiro-qutnolylhydantoin derivatives of the formula:n and the base salts thereof with pharmaceutically acceptable cations, wherein X is oxygen or sulfur; n is zero, one or two;n R is hydrogen, alkyl of 1 to 4 carbon atoms or benzyl; and R,, R 2 and R 3 are each hydrogen, chloro, bromo, fluoro, alkyl of 1 to 3 carbon atoms or phenyl, are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications. n Preferred compounds include spiro[imidazolidin-4,4'--pyrano(3,2-h)quinolin]-2,5-dione and spiro[imidazolidin--4,4'-pyrano(2,3-f)quinolin]-2,5-dione. |